捷強裝備(300875.SZ)：擬收購北京三安新特生物科技51%股權
格隆匯 1 月 19日丨捷強裝備(300875.SZ)公佈，公司董事會於2021年1月19日召開第二屆董事會第十七次會議，審議通過了《關於擬收購北京三安新特生物科技有限公司51%股權的議案》，同意公司與應天翼簽訂《股權轉讓協議》，以自有資金收購北京三安新特生物科技有限公司(“三安新特”或“目標公司”)51%的股權。經綜合考慮目標公司業務發展情況、與公司的協同效應及未來盈利能力等，依據謹慎性原則，經交易各方友好協商後確定此次股權收購的價格不超過人民幣3500萬元。此次交易完成後，目標公司將成為公司的控股子公司，並納入公司合併報表範圍。
三安新特專注於特種生物檢測技術在環境公共安全監測領域應用，開發相關生物安全系列產品，為客户提供特種生物安全監測與檢測整體解決方案。聚焦免疫檢測與核酸檢測技術，技術成熟且具備產品全流程自主研發與生產製造能力。其目前在免疫檢測、核酸檢測及配套設備領域的主營產品有：針對多種細菌、真菌、病毒、毒素及毒麻品的現場快速檢測試紙卡(膠體金、時間分辨熒光)及檢測裝備、濕壁氣旋式氣溶膠採樣設備、部隊防化及防生配套訓練器材。主要應用于軍隊系統、警用反恐、公安內衞、各級應急保障分隊、各級疾病預防控制中心(CDC)、食品安全部門與科研單位等。
在此次交易中，圍繞公司“平戰一體的核化生防禦裝備全產業鏈”的發展戰略，基於對目標公司管理團隊的科研實力、業務拓展能力，以及目標公司的未來盈利能力及民用產品研發及轉化能力的評估，主要目的是進一步推進公司在生物領域的基本佈局，對公司在未來核化生一體防禦裝備領域的業務拓展形成有力的支撐。
為此，公司整合資源，利用雙方優勢共同合作，進一步拓展生物相關領域的軍品及民用市場，從而增強公司在核化生防禦裝備領域的核心競爭力，提升公司業績，符合公司和全體股東的利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
